Introduction {#s1}
============

The introduction of immune checkpoint inhibitors (ICIs) in the oncological therapeutic arsenal has brought significant benefits for patients, leading to long-lasting tumor responses ([@B18]). Therefore, these innovative drugs are increasingly used. ICIs are mainly represented by monoclonal antibodies able to target programmed cell death receptor or its ligand (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). PD-1, PD-L1, and CTLA-4 are immune checkpoints, markedly overexpressed in the tumor microenvironment and involved in the inhibition of T cell signals ([@B48]). The expression of these immune checkpoints is one of several tumors adaptive responses to escape the immune system ([@B20]; [@B26]). Blocking these negative costimulatory molecules, ICIs re-establish the ability of cytotoxic T cells to destroy tumor cells. Acting on immune cells rather than cancer ones ([@B51]), ICIs have revolutionized the treatment of several types of cancer, leading to a substantial shift in oncology paradigms. Currently, seven ICIs are available in the European pharmaceutical market: the CTLA-4 inhibitor (CTLA-4i) ipilimumab (authorized in 2011); PD-1 inhibitors (PD-1i), nivolumab (2015), pembrolizumab (2015), and cemiplimab (June 2019); PD-L1 inhibitors (PD-L1i), atezolizumab (2017), avelumab (2017), and durvalumab (2018). Since the inhibition mediated by the association nivolumab/ipilimumab turns out better in improving anti-tumor responses in metastatic melanoma, the combination therapy was also authorized in May 2016 ([@B45]). Despite their proven clinical efficacy, ICIs, as all monoclonal antibodies, are related to a new type of drug-toxicity ([@B2]), which includes immune-related ADRs (irADRs) ([@B19]). IrADRs might represent the consequence of the effects resulting from T cells acting against antigens shared by tumor and normal cells or from the concomitant activation of multiple T cell populations ([@B13]). On the other hand, their occurrence is strictly related to ICIs' pharmacodynamic properties. Indeed, it is known that ICI-target immunosuppressive molecules are involved in self-tolerance as well in various autoimmune conditions ([@B2]). Acting on the immune system, ICI-induced irADRs can involve any tissue and organ and can occur anytime ([@B26]). However, differences in terms of types, rates, time to onset, and seriousness of irADRs have been described for CTLA-4i and PD-1/PD-L1i ([@B27]). Literature data highlighted that ICI-induced irADRs could occur more frequently than expected, such as in the case of gastrointestinal immune-related events, which are likely to be encountered more frequently by gastroenterologists, who will need to be aware of these ADRs. Therefore, the early recognition and treatment are very critical steps ([@B43]). Indeed, if not promptly recognized and properly managed (i.e., using corticosteroids or immunosuppressive drugs and/or suspending suspected drugs), irADRs can be life-threatening ([@B53]). Two recent pharmacovigilance studies have investigated the safety profile of ICIs, in terms of irADRs, using data from the international surveillance databases VigiBase. Among these, Salem et al. evaluated the association between ICIs and CV events. Their findings highlighted that ICIs were associated with higher reporting of myocarditis, pericardial diseases, and vasculitis. These CV-irADRs affected most commonly men and tended to occur within one month of the first ICI administration([@B34]). Johnson et al. evaluated instead neurologic ADRs in patients receiving ICIs. The results revealed that ICIs were associated with higher incidence of myasthenia gravis (ROR, 16.5; 95% confidence interval \[95% CI\], 14.5--18.9; IC025, 3.31), encephalitis (ROR, 10.4; 95% CI, 9.2--11.8; IC025, 3.15), and meningitis (ROR, 3.1; 95% CI, 2.5--3.9; IC025, 1.01). Most of these ADRs were considered as irADRs ([@B43]). Therefore, many studies have already investigated the occurrence of specific subtypes of irADRs related to ICIs, using data from post-marketing surveillance database, but to our knowledge no studies have investigated the reporting of all ICI-induced irADRs in the Italian context.

Given the clinical relevance of ICI-induced irADRs and considering that underlying mechanisms are still not completely understood ([@B31]), as for any other innovative drug, extensive safety monitoring is highly recommended ([@B7]). Therefore, in order to extrapolate as much information as possible from the context of clinical practice ([@B39]), we analyzed individual case safety reports (ICSRs) related to ICIs, collected into the National Pharmacovigilance Network (Rete Nazionale di Farmacovigilanza, RNF) focusing on those reporting irADRs, with a specific analysis in the Campania Region (South of Italy).

Materials and Methods {#s2}
=====================

Data Source {#s2_1}
-----------

In Italy, pharmacovigilance activities are coordinated by the Italian Medicine Agency (AIFA), which instituted in 2001 the RNF, a national pharmacovigilance database. The RNF allows the collection, management, and analysis of ICSRs reporting ADRs, defined by Directive 2010/84/EU, occurring throughout the national territory ([@B41]). In Italy, Pharmacovigilance Regional Centers (PRCs) contribute to the evaluation of the quality of collected data and the causality assessment for each drug or vaccine/ADR couple cooperating with AIFA to vaccines and drug safety signal detection. Each PRC can access to ICSRs collected in the RNF that refer to ADRs occurred in its competence territory, on which it may conduct further analysis such as preventability of reported ADRs ([@B42]; [@B22]). Moreover, starting from July 2017, the AIFA has set up an online open-access system (report Reazioni Avverse dei Medicinali, RAM), which allows access to some data relating to ICSRs recorded into the RNF starting from 2002. Data available from the RAM system can contribute to obtaining an overview of ADRs that occur at a national level. Therefore, we retrieved from the RAM system (for national safety data) and the RNF (for Campania safety data) all ICSRs reported from January 1, 2001, to February 28, 2019, in which pembrolizumab, nivolumab, ipilimumab, atezolizumab, avelumab, or durvalumab were indicated as suspected drug. Cemiplimab was not considered in our analysis given its recent authorization.

Descriptive and Disproportionality Analyses {#s2_2}
-------------------------------------------

First, we carried out a descriptive analysis of all national ICI-related ICSRs in terms of number of ICSRs, seriousness, gender, age groups, System Organ Class (SOC), and p-term of irADRs ([**Table 1 Supplementary Materials**](#SM1){ref-type="supplementary-material"}) both for the entire ICIs class and single active substance. Moreover, we performed a descriptive analysis of ICI-related ICSRs reported in the Campania Region, focusing on those reporting irADRs. These regional ICSRs were stratified by suspected drugs, concomitant drug(s), therapeutic indication, median age (IQR), gender, seriousness (serious or non-serious/non-defined), time to event (TTE), time to resolution of event(s) (TTR), outcome, causality assessment, and irADR(s) management. According to current pharmacovigilance regulations, all ADRs that induced death, hospitalization or prolongation of hospitalization, severe or permanent disability, life threat, congenital abnormalities/birth deficits or considered as clinically relevant were categorized as serious. The outcome was categorized as favorable if irADR was completely resolved or improved, while as unfavorable if irADR resolved with sequelae, was unchanged or induced patient's death. The causality assessment was performed through the Naranjo algorithm ([@B28]). We used the chi square test, the Mann-Whitney U test, or the Fisher exact test (where appropriate) to evaluate if differences were statistically significant (*p* \< 0.05). Finally, we performed a disproportionality analysis of national and regional ICI-induced irADRs cases, through the reporting odds ratio (ROR) with 95% CI, using other ICIs as comparison. The signal was considered statistically significant when the lower limit of 95% CI of a ROR exceeded 1.0.

Results {#s3}
=======

National Results {#s3_1}
----------------

From January 1, 2002, to February 28, 2019, the reporting of ICI-induced ADRs progressively increased; this growth was more evident for nivolumab-related ICSRs since 2015 ([**Figure 1**](#f1){ref-type="fig"}). ICSRs related to ipilimumab before the authorization date may represent those collected in the context of clinical trials or compassionate use programs. Overall 2088 ICSRs with an ICI as suspected drug were collected in the RNF and listed in the RAM system. About 70% of these ICSRs were related to nivolumab (n = 1,452), followed by ipilimumab (n = 318; 15%), pembrolizumab (n = 230; 11%), atezolizumab (n = 78; 4%), and avelumab (n = 9; \< 1%). Only 1 ICSR reported durvalumab as suspected drug. Demographic characteristics and seriousness classification of national ICSRs stratified for each ICI are shown in [**Table 1**](#T1){ref-type="table"}. No substantial difference emerged in terms of seriousness for any single drug. The majority of ICSRs reported ADRs that occurred in male patients (\> 58% for each single ICI) and in the age group \> 66 years, except for ipilimumab, for which ADRs were more frequently reported in the age group 18 to 65 years. Gender differences were statistically significant for nivolumab (p \< 0.05), ipilimumab (p \< 0.001), and atezolizumab (p \< 0.05) (data not shown). In the analysis of distribution of ICI-induced ADRs for SOCs, we found a greater involvement of "General disorders and administration site conditions" (n = 558; 14%), "Respiratory, thoracic, and mediastinal disorders" (n = 485; 12%), and "Gastrointestinal disorders" (n = 481; 12%), followed by "Skin and subcutaneous tissue disorders" (n = 414; 10%), "Investigations" (n = 354; 9%), and "Musculoskeletal and connective tissue disorders" (n = 195; 5%) (data not shown).

![Trend of number of ICI-related ICSRs from January 1, 2002, to February 28, 2019, collected into the RNF and listed in the RAM system.](fphar-11-00830-g001){#f1}

###### 

ICI-related ICSRs collected into the RNF from January 1, 2002, to February 28, 2019 stratified by seriousness, gender, and age groups (data available from the RAM system).

  ICI as suspect drug   Tot. ICSRs   Seriousness   Gender   Age Groups                                     
  --------------------- ------------ ------------- -------- ------------ ----- ----- ---- ---- ----- ----- -----
  **Nivolumab**         1452         695           635      122          958   430   64   4    540   708   200
  **Ipilimumab**        318          157           150      11           185   129   4    1    174   128   15
  **Pembrolizumab**     230          131           98       1            152   74    4    --   87    121   22
  **Atezolizumab**      78           38            38       2            61    16    1    --   17    42    19
  **Avelumab**          9            5             4        --           6     2     1    --   1     7     1
  **Durvalumab**        1            1             --       --           --    1     --   --   1     --    --

N.A, Not Available.

### National irADRs Results {#s3_1_1}

Among 2088 ICSRs, we found that 20% of all ADRs were immune-related (801/3988). Majority of these irADRs were signs or symptoms of gastrointestinal toxicity (33%; mainly represented by diarrhea, pancreatitis, and enterocolitis), followed by skin toxicity (17%; mainly itch, psoriasis, and macular-papular rash) and pulmonary disorders, such as pneumonia and pleurisy (16%) ([**Table 2**](#T2){ref-type="table"}). Moreover, several irADRs involved also the hematologic and endocrine systems. While pulmonary ADRs were mainly induced by both nivolumab and ipilimumab (59/129 and 57/129, respectively), most hematologic irADRs were related to nivolumab (81/98). IrADRs involving cardiovascular and renal systems were less frequently reported. Nivolumab was the ICI most commonly reported as suspected drug (n = 478), followed by ipilimumab (n = 192) and pembrolizumab (n = 106). A statistically significant ROR was found for ipilimumab and pembrolizumab ([**Figure 2A**](#f2){ref-type="fig"}). According to the results of disproportionality analysis, a statistically significant ROR was found for ipilimumab (ROR, 2.9050; 95% CI, 2.2733--3.7122) and pembrolizumab (ROR, 1.4305; 95% CI, 1.0857--1.8847) ([**Figure 2A**](#f2){ref-type="fig"}). Therefore, ipilimumab and pembrolizumab were associated with an increased reporting probability of irADRs rather than no-irADRs if compared to other ICIs.

###### 

ICI-induced irADRs reported from January 1, 2002, and February 28. 2019 and collected into the RNF (data available from the RAM system).

  --------------------------------------------------------------------------------------------------------
  TOXICITY TYPE                   *Tot. irADRs*\   *ICIs*                                          
                                  *n (%)*                                                          
  ------------------------------- ---------------- ---------- --------- ------- ---------- ------- -------
  **Gastrointestinal Toxicity**   264 (33)         132 (50)   22 (8)    2 (1)   108 (41)   \-      \-

  Diarrhea                        225              115        11        2       97         --      --

  Pancreatitis                    20               12         6         --      2          --      --

  Enterocolitis                   12               5          5         --      2          --      --

  Celiac Disease                  3                --         --        --      3          --      --

  Gastritis                       2                --         --        --      2          --      --

  Ileitis                         2                --         --        --      2          --      --

  **Skin Toxicity**               139 (17)         103 (74)   22 (16)   8 (6)   6 (4)      \-      \-

  Itch                            94               71         16        6       1          --      --

  Psoriasis                       20               15         2         2       1          --      --

  MP Rash                         13               10         2         --      1          --      --

  SJS                             8                4          2         --      2          --      --

  Vitiligo                        4                3          --        --      1          --      --

  **Pulmonary Toxicity**          129 (16)         59 (46)    11 (8)    1 (1)   57 (44)    \-      1 (1)

  Pneumonia                       87               59         11        1       15         --      1

  Pleurisy                        42               --         --        --      42         --      --

  **Hematological Toxicity**      98 (12)          81 (83)    8 (8)     9 (9)   --         --      --

  Hemolytic Anemia                41               37         --        4       --         --      --

  Thrombocytopenia                37               31         2         4       --         --      --

  Neutropenia                     20               13         6         1       --         --      --

  **Endocrine Toxicity**          91 (11)          52 (57)    17 (19)   1 (1)   21 (23)    \-      \-

  Hyperthyroidism                 36               32         --        1       3          --      --

  Hypothyroidism                  18               5          10        --      3          --      --

  Hypophysitis                    16               7          5         --      4          --      --

  Adrenal insufficiency           16               7          2         --      7          --      --

  Diabetes                        5                1          --        --      4          --      --

  **Liver Toxicity**              22 (2.7)         11 (50)    10 (45)   1 (5)   \-         \-      \-

  Hepatitis                       22               11         10        1       --         --      --

  **Musculoskeletal Toxicity**    19 (2.4)         14 (74)    4 (21)    1 (5)   \-         \-      \-

  Arthritis                       11               9          1         1       --         --      --

  Myositis                        7                5          2         --      --         --      --

  Myopathies                      1                --         1         --      --         --      --

  **Central Toxicity**            16 (2)           8 (50)     7 (44)    \-      \-         1 (6)   \-

  Neuropathy                      7                4          3         --      --         --      --

  Encephalitis                    6                4          2         --      --         --      --

  GBS                             2                --         2         --      --         --      --

  Myasthenia                      1                --         --        --      --         1       --

  **Ocular Toxicity**             9 (1.1)          8 (89)     1 (11)    \-      \-         \-      \-

  Conjunctivitis                  6                6          --        --      --         --      --

  Uveitis                         3                2          1         --      --         --      --

  **Renal Toxicity**              7 (0.9)          5 (71)     2 (29)    \-      \-         \-      \-

  Nephritis                       7                5          2         --      --         --      --

  **Cardiovascular Toxicity**     7 (0.9)          5 (71)     2 (29)    \-      \-         \-      \-

  Myocarditis                     4                3          1         --      --         --      --

  Pericarditis                    2                1          1         --      --         --      --

  Vasculitis                      1                1          --        --      --         --      --
  --------------------------------------------------------------------------------------------------------

MP rash, maculo-papular rash; SJS, Steven Johnson's syndrome; GBS, Guillain-Barré syndrome.

![Disproportionality analyses of the national **(A)** and regional data **(B)**.](fphar-11-00830-g002){#f2}

Campania Region Results {#s3_2}
-----------------------

In the same study period, 253 ICSRs related to ICIs were sent to the Campania PRC. All ICSRs were spontaneous reports, except for 4 ICSRs collected within a non-interventional multiregional study (MEREAFAPS study) (data not shown) ([@B30]). The majority of ICSRs reported not-serious ADRs (N = 176; 69%) ([**Table 2 Supplementary Materials**](#SM1){ref-type="supplementary-material"}). Nivolumab was most commonly reported suspected drug (N = 172; 68%), followed by ipilimumab (N = 45; 17.8%), and pembrolizumab (N = 33; 13%). There were only three ICSRs related to atezolizumab and none related to avelumab, durvalumab, or the combination therapy. Serious ADRs were reported in almost 30% of all ICSRs for each ICI, except for pembrolizumab, which had the lowest percentage of serious ADRs (15.2%). Demographic and clinical characteristics of overall cases are shown in [**Table 3**](#T3){ref-type="table"}. ICI-induced ADRs occurred in patients with a median age of 66 years (IQR, 57--72 years) and no difference were found for irADRs, likewise no-irADRs occurred in patients with a median age of 65.5 years (IQR, 57--71.5 years). Both immune- and non-immune-related ADRs occurred mainly in male patients, with a slightly higher percentage of no-irADRs compared to irADRs in males (65.9% vs. 54.5%); no statistically significant difference emerged in terms of gender (p \> 0.05). The majority of ICSRs reported ADRs that were classified as not serious (69.6%). The percentage of not serious ADRs was higher for no-irADRs compared to irADRs (78.8% vs. 59.5%, respectively), while the opposite was found for serious ADRs (19.7% vs. 37.2%, respectively). Comparing the seriousness degree for irADRs and no-irADRs, a statistical significant difference was found (p \< 0.05). Among ICSRs reporting serious ADRs, the most common seriousness criteria was "clinical relevant" both for irADRs and no-irADRs (26.4% vs. 15.2%). Differences were not statistically significant. The majority of ICSRs reported ADRs with a favorable outcome (60.9%), and no statistically significant differences were found between ICSRs reporting irADRs and no-irADRs. Among ICSRs reporting unfavorable outcomes (N = 67; 26.5%), eight cases (seven related to nivolumab and one to ipilimumab) resulted in patient's death ([**Table 4**](#T4){ref-type="table"}), mainly due to ADRs involving respiratory and cardiac systems. In 2 cases (cases n. 4 and 5), the reporter specified that patient's death was considered as related to the patient's clinical conditions.

###### 

Demographic and clinical characteristics of ICI-related irADRs cases and no-irADRs cases sent through the Campania Region spontaneous reporting system from January 2001 to February 2019.

  Variable                                                   Level          All cases, N = 253 (100%)   irADR cases, n = 121 (47.8%)   No-irADRs cases, n = 132 (52.2%)   p-value (\< 0.05)
  ---------------------------------------------------------- -------------- --------------------------- ------------------------------ ---------------------------------- -------------------
  **Age**                                                    Median (IQR)   66 (57--72)                 66 (58--73)                    65.5 (57--71.5)                    \>0.05\*
  Missing                                                    9              5                           4                                                                 
  **Gender**                                                                \>0.05\*\*                                                                                    
  Male                                                       153 (60.5)     66 (54.5)                   87 (65.9)                                                         
  Female                                                     94 (37.1)      49 (40.5)                   45 (34.1)                                                         
  Missing                                                    6 (2.4)        6 (5)                       --                                                                
  **Seriousness of adverse events**                                         0.001978                                                                                      
  Not serious                                                176 (69.6)     72 (59.5)                   104 (78.8)                                                        
  Serious                                                    71 (28)        45 (37.2)                   26 (19.7)                                                         
  NA                                                         6 (2.4)        4 (3.3)                     2 (1.5)                                                           
  **Seriousness criteria**                                                  \>0.05                                                                                        
  Clinically relevant                                        52             32 (26.4)                   20 (15.2)                                                         
  Hospitalization or its prolongation                        15             11 (9)                      4 (3)                                                             
  Death                                                      3              1 (0.8)                     2 (1)                                                             
  Life-threating                                             1              1 (0.8)                     --                                                                
  **Outcome**                                                               \>0.05                                                                                        
  Favorable (completely resolved or improved)                154 (60.9)     71 (58.7)                   83 (62.9)                                                         
  Unfavorable (death, unchanged or resolved with sequelae)   67 (26.5)      39 (32.2)                   49 (37.1)                                                         
  Not available                                              32 (12.6)      11 (9.1)                    21 (15.9)                                                         
  **Suspected drugs**                                        Nivolumab      172 (68)                    74 (61.2)                      98 (74.3)                          0.025845
  Ipilimumab                                                 45 (17.8)      34 (28.1)                   11 (8.3)                       0.00004                            
  Pembrolizumab                                              33 (13)        12 (9.9)                    21 (15.9)                      \>0.05                             
  Atezolizumab                                               3 (1.2)        1 (0.8)                     2 (1.5)                        \>0.05                             

\* Value of the Mann-Whitney U Test.

\*\* Value of the Fisher exacts test statistic.

###### 

ICSRs sent to the Campania Pharmacovigilance Regional Centre from January 2001 to February 2019 reporting immune-related adverse drug reactions resulted in patient's death.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case n.   Age (years)   Sex   Suspected drugs   Ther. Indic.   Concomitant drugs                                         ADR(s)                                                                       TTE (days)   TTD (days)   Causality Assessment
  --------- ------------- ----- ----------------- -------------- --------------------------------------------------------- ---------------------------------------------------------------------------- ------------ ------------ ----------------------
  **1**.    78            F     Ipilimumab        Mel. M.        --                                                        Diarrhea, Thrombocytopenia                                                   65           \~3          Possible

  **2**.    72            M     Nivolumab         L.C.           --                                                        Autoimmune hepatitis                                                         3            9            Possible

  **3**.    57            F     Nivolumab         L.C.           Zoledronic Acid                                           Dyspnea,\                                                                    10           6            Possible
                                                                                                                           Peripheral edema                                                                                       

  **4**.    66            F     Nivolumab         L.C.           Metformin Levothyroxine Alprazolam Paroxetine Trazodone   Respiratory failure                                                          25           1            Possible

  **5**.    50            M     Nivolumab         L.C.           --                                                        Cardiac arrest                                                               18           18           Possible

  **6**.    70            M     Nivolumab         Mel.           --                                                        Pneumonia, death                                                             N.A.         N.A.         Possible

  **7**.    66            F     Nivolumab         L.C.           Levothyroxine                                             AV block, eyelid ptosis, hypophysitis, myasthenia, diarrhea, and pneumonia   \~21         \~210        Possible

  **8**.    67            M     Nivolumab         L.C.           Acetylsalicylic acid                                      Hemoptysis                                                                   15           7            Possible
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mel. M., metastatic melanoma; L.C., lung cancer; Mel., melanoma; AV block, atrioventricular block.

### Campania Region irADRs Results {#s3_2_1}

One-hundred-twenty-one out of 253 ICSRs sent to the Campania PRC reported an ICI-induced irADRs (47.8%), which were serious in 37.2% of cases (including several 3--4 grade cases) and had unfavorable outcome in 32.2% of cases. Four irADRs were fatal (cases n. 1, 2, 6, and 7 reported in [**Table 4**](#T4){ref-type="table"}). Nivolumab was the ICI most commonly involved in the occurrence of irADRs (N = 74) ([**Table 3**](#T3){ref-type="table"}), but the majority of these had favorable outcomes. Statistically significant differences in terms of irADR/no-irADRs cases emerged for both nivolumab and ipilimumab (p \< 0.05). Looking at each single ICI, the majority of ipilimumab-induced ADRs were irADRs (75.5%), with unfavorable outcomes in most of the cases (61.8%). Pembrolizumab-induced irADRs were those with the most commonly favorable outcome (75%). Moreover, more than 33% of irADRs reported for each ICI were serious ([**Table 3 Supplementary Materials**](#SM1){ref-type="supplementary-material"}). The majority of irADRs involved skin disorders (mainly represented by itch and psoriasis nivolumab-induced), followed by gastrointestinal toxicity (mainly ipilimumab-induced diarrhea) ([**Table 5**](#T5){ref-type="table"}). Several cases of irADRs involved the endocrine system, such as hypothyroidism and hypophisitis, which were mainly induced by nivolumab. Moreover, nivolumab was the ICI most commonly involved in several cases of pneumonia and thrombocytopenia. The causality assessment was possible for most cases. Concomitant diseases were reported in 19% of cases, and those most commonly reported were cardiovascular (i.e., hypertension, myocardial infarction, atrial fibrillation), and endocrine disorders (i.e., diabetes mellitus 2, hypothyroidism, multinodular goiter). We found a case of nivolumab-induced pancreatic toxicity occurred in a 71 years old patient with HCV-related hepatocarcinoma. Only 15 ICSRs reported concomitant drugs (≥3 concomitant drugs per ICSR), mainly represented by cardiovascular and lipid-lowering drugs.

###### 

ICI-induced immune-related adverse drug reactions reported in the Campania Region and collected into the RNF.

  ---------------------------------------------------------------------------------------------
  TOXICITY TYPEs                  irADRs\      ICIs                                  
                                  N=132                                              
  ------------------------------- ------------ ------------ ------------ ----------- ----------
  **Skin Toxicity**               49 (37.1%)   30 (35.3%)   12 (35.3%)   7 (58.3%)   --

  Itch                            32           15           12           5           

  Psoriasis                       6            6            --           --          

  Macular-papular rash            4            4            --           --          

  Vitiligo                        3            3            --           --          

  Epidermolysis bullosa           2            --           --           2           

  Pemphigus                       2            2            --           --          

  **Gastrointestinal toxicity**   32 (24.2%)   14 (16.5%)   17 (50%)     1 (8.3%)    --

  Diarrhea                        24           9            14           1           

  Enterocolitis                   4            1            3            --          

  Pancreatitis                    4            4            --           --          

  **Endocrine toxicity**          22 (16.7%)   19 (22.4%)   --           2 (16.7%)   1 (100%)

  Hypothyroidism                  13           11                        2           --

  Hypophysitis                    3            3                         --          --

  Thyroiditis                     3            3                         --          --

  Hyperthyroidism                 2            2                         --          --

  Thyrotoxicosis                  1            --                        --          1

  **Pulmonary toxicity**          9 (6.8%)     6 (7.1%)     1 (2.9%)     2 (16.7%)   --

  Pneumonia                       8            6            1            1           

  Respiratory failure             1            --           --           1           

  **Hematological toxicity**      7 (%)        5 (5.8%)     2 (5.9%)     --          --

  Thrombocytopenia                6            5            1                        

  Neutropenia                     1            --           1                        

  **Liver toxicity**              5 (3.8%)     3 (3.5%)     2 (5.9%)     --          --

  Hepatitis                       5            3            2                        

  **Musculoskeletal toxicity**    3 (2.3%)     3 (3.5%)                              --

  Myositis                        2            2                                     

  Arthritis                       1            1                                     

  **Central toxicity**            3 (2.3%)     3 (3.5%)     --           --          --

  Neuropathy                      1            1                                     

  Encephalitis                    1            1                                     

  Myasthenia                      1            1                                     

  **Ocular toxicity**             1 (0.8%)     1 (1.2%)     --           --          --

  Uveitis                         1            1                                     

  **Renal toxicity**              1 (0.8%)     1 (1.2%)     --           --          --

  Nephritis                       1            1                                     
  ---------------------------------------------------------------------------------------------

Details of meaningful reported ICI-induced cases were described in [**Table 4 of Supplementary Materials**](#SM1){ref-type="supplementary-material"}. The reporter specified the autoimmune etiology of the ADR in 6 ICSRs, reporting cases of hepatitis (N = 3), encephalitis (N = 1), hypothyroidism (N = 1), and pancreatitis (N = 1). In most cases, irADRs were managed with ICI discontinuation and the administration of high-dose corticosteroids. The corticosteroids administration allowed favorable outcomes in 75% of cases in which they were administered. Lastly, among many serious irADRs involving the gastrointestinal system, we found 2 cases of ipilimumab-induced diarrhea, which required the administration of infliximab to manage the ADR. Infliximab administration allowed the improvement of ADR in one of these cases. The median TTE was 51 days (IQR, 26--105.5), and the median TTR was 15.5 days (IQR, 6.5--20.25) ([**Figure 3A**](#f3){ref-type="fig"}) for the entire ICI class. Comparing TTE related to nivolumab and ipilimumab, which were ICIs most frequently reported, we found that ipilimumab-induced events occurred earlier compared to nivolumab, with median TTE of 42 days (IQR, 23--60.25) and 63 days (IQR, 30.25--160), respectively ([**Figure 3B**](#f3){ref-type="fig"}). All ipilimumab-induced irADRs occurred within 9 weeks. Hepatic, gastrointestinal, and skin toxicity occurred earlier. Nivolumab-induced endocrine and skin irADRs occurred later ([**Figure 4**](#f4){ref-type="fig"}). According to the results of disproportionality analysis, ipilimumab was associated with an increased reporting probability of irADRs rather than no-irADRs if compared to other ICIs. In fact, a statistically significant ROR emerged only for ipilimumab ([**Figure 2B**](#f2){ref-type="fig"}). Finally, excluding ipilimumab-induced irADRs cases and comparing only PD-L1i and PD-1i cases, a statistically significant ROR was not found (ROR, 1.3699; 95% CI, 0.8528--2.2006) (data not shown).

![**(A)** Median time to event and median time to resolution of ICI-induced irADRs reported in the Campania Region and collected into the RNF from January 1, 2001, to February 28, 2019. **(B)** Comparing median time to event of nivolumab- and ipilimumab-induced irADRs reported in Campania Region and collected in RNF from January 1, 2001, to February 28, 2019.](fphar-11-00830-g003){#f3}

![Distribution of median time to event of ipilimumab- and nivolumab-induced irADRs reported in the Campania Region and collected into the RNF from January 1, 2001, to February 28, 2019 stratified by toxicity types.](fphar-11-00830-g004){#f4}

Discussion {#s4}
==========

Our study aimed to analyze ICI-induced irADRs collected in the Italian pharmacovigilance database, with a focus on the Campania Region. To our knowledge, this study represents the first comprehensive evaluation of safety data related to ICIs using the Italian spontaneous reporting system. During ICIs treatment irADRs is quite common, with an incidence of 90% for any-grade irADRs, even though in most cases these are mild and transient ([@B33]). In our study, irADRs represented 20% of all ICI-related ADRs collected into the RNF. In the Campania Region almost half of ICI-related ICSRs reported irADRs. Differences in terms of safety have been highlighted among different ICIs classes. IrADRs incidence seems to be higher with ipilimumab than nivolumab and pembrolizumab ([@B3]; [@B25]; [@B49]). It has been hypothesized that the CTLA-4 inhibition induces a larger T-cell proliferation, while PD-1 blockade leads to an activation of a smaller number of T-cell clones. Slight differences in toxicity profiles of PD-1i and PD-L1i have also been found, but to date clinical data are limited ([@B49]). In line with literature data, in our study ipilimumab treatment appeared unwieldy compared to other ICIs, especially for the onset of serious irADRs with unfavorable outcomes. This seems to be confirmed also by significant statistically ROR emerged for both national and regional data. Statistically significant ROR emerged also for pembrolizumab from disproportionality analysis of national data, showing that also this treatment could increase the risk of reporting irADRs compared to other ICIs. On the contrary, although nivolumab was the ICI reported as suspected drug in the highest number of ICSRs, it was not associated with an increased reporting probability of irADRs compared to no-irADR when compared to the other ICIs, resulting in a safe and widely used drug. Due to their better safety profiles, PD-1i and PD-L1i are more commonly used than CTLA-4i ([@B27]). Furthermore, nivolumab showed equivalent efficacy profile compared to ipilimumab ([@B55]). This evidence could justify the larger number of ICSRs related to nivolumab.

We have found statistically significant gender-differences in our national analysis. Specifically, nivolumab-, ipilimumab-, and atezolizumab-induced ADRs were more commonly reported in males compared to females. Sex-based immunological differences, expressed in different immune responses to infections as well as in different predisposition to develop autoimmune diseases are reported in literature ([@B47]). However, the gender-influence on the efficacy and safety of immunotherapy treatments seems to be controversial ([@B10]; [@B9]; [@B12]; [@B52]). What we have found should be related to gender differences in incidence rates of diseases representing therapeutic indications of ICIs treatment. For example, highest lung cancer and melanoma incidence rates have been recognized in men ([@B50]; [@B44]). Furthermore, our result should be related to the hypothesized but still debated ([@B31]) correlation between irADRs onset and immunotherapy efficacy ([@B16]; [@B36]), the latter seems to be superior in men ([@B9]; [@B12]; [@B57]). Since ICIs act on the immune system, irADRs can involve any tissue and organ, probably due to activation of autoreactive T cells damaging host tissues ([@B35]). As confirmed from our analysis, the majority of irADRs expressed mainly in cutaneous and gastrointestinal toxicity ([@B27]). We found two cases, both induced by ipilimumab, of severe diarrhea that required infliximab administration. According to the ESMO guidelines, infliximab treatment is necessary when high corticosteroids administration have been not sufficient to manage the irADR ([@B14]; [@B15]). Rare irADRs, like renal, cardiac, and ocular ADRs, have been reported, confirming that such ADRs occurred less frequently ([@B33]). From the national data set, beyond irADR involving skin and gut, we found several cases of pulmonary and hematologic toxicities, although generally these systems are involved less often in irADRs ([@B49]). On the other hand, in the regional dataset, we found several cases of irADRs involving the endocrine system, such as hypothyroidism and thyroiditis, mainly due to nivolumab-treatment. According to literature data, it seems that thyroiditis is more common with PD-1i ([@B33]). In this respect, cases reported in our study were all nivolumab-induced. Regarding timing of onset, except for a slight delay of nivolumab-induced skin toxicity, median TTEs are consistent with the timing emerged during the clinical studies, for both nivolumab and ipilimumab ([@B49]). Events mainly occurred within the first 3 months from the starting of the treatment. Moreover, our results confirmed that ipilimumab-induced ADRs occur earlier than ones induced by nivolumab. This could be related to different functions of CTLA-4 and PD-1 in the immune response ([@B3]). CTLA-4 is involved in proximal steps, while PD-1 takes part in later stages of the immune response ([@B54]; [@B49]).

According to Champiat et al., both concomitant diseases and drugs could promote the onset of irADRs ([@B4]). In our results, among drugs already related to autoimmune toxicity and so considered such as predisposing drugs to irADRs ([@B5]), antihypertensive (such as atenolol) and lipid-lowering drugs (such as atorvastatin) were those most commonly reported. This could be related to the ability of atenolol to induce the formation of anti-histone antibodies, which are more expressed in patients affected by autoimmune diseases ([@B11]; [@B23]). In the same way, also statins seem to be able to modulate the immune system through different mechanisms, inducing possible development of autoimmune diseases ([@B6]). Other possible risk factors for irADRs seem to be concomitant diseases. From our analysis, we found several cases of thyroid disorders and one of HCV-hepatitis. HCV infection has been associated to various immune and autoimmune disorders. In case of failure in the virus eradication process, a persistent infection could lead to excessive immune stimulation through a humoral and cell-mediated response, whose dysfunction has been associated with the increase of immune complexes and autoantibodies, responsible for immune disorders ([@B24]; [@B29]). A recent meta-analysis showed that most of CTLA-4 deaths occurred in patients who experienced colitis, while fatalities related to PD-1/PD-L1i occurred in patients who experienced pneumonitis, hepatitis, and neurotoxic effects ([@B2]). In line with this, autoimmune hepatitis and pulmonary disorders were reported in 4 out of 6 fatal cases related to nivolumab. The only one fatal case induced by ipilimumab was due to severe thrombocytopenia. Although hematologic ADRs rarely occur during ICIs treatment, thrombocytopenia could be caused by autoantibodies that bind platelet epitope, such as glycoproteins, interfering with their function ([@B46]; [@B32]). Among our fatal cases, a nivolumab-related cardiac arrest has been reported. Cardiac arrest could be the result of acute myocarditis, a well-known ICI-related cardiac irADR ([@B1]). According to Johnson et al the presence of an antigen shared between cancer cells and myocardiocytes may explain ICI-induced myocarditis. Whilst the activated T cells are able to provide an anti-tumor response binding to the antigen expressed on tumor cells, they could induce inflammation and necrosis of myocardiocytes, by penetrating the myocardium ([@B17]). Generally, cardiac irADRs are less common.

Strengths and Limitations {#s5}
=========================

Although the spontaneous reporting system is a cornerstone of pharmacovigilance activities, it is characterized by intrinsic limitations such as the under-reporting, that is the failure to report a suspected ADR by medical or healthcare personnel, and the possible incorrect or incomplete information reported in the ICSR. Given these limitations and considering that ICI-prescription were not available, we were not able to define the real incidence of ICI-induced irADRs neither to establish which ICI was associated with the greatest number of irADRs.

Despite these limitations, it is largely recognized that the spontaneous reporting system represents a simple, useful, and inexpensive pharmacovigilance tool. Analysis of spontaneous reporting data contributes to a better characterization of the drug safety profiles, especially for newly authorized medicines. It allows detecting rare and serious ADRs detectable only in the post-marketing phase when a larger population compared to those in clinical trials use drugs. Furthermore, the spontaneous reporting system involves ICSRs related to frail population, including elderlies and patients with multiple comorbidities, that are usually excluded by the premarketing clinical trials; therefore, data obtained from the spontaneous reporting system represent one of the main source of information for these population. Lastly, considering the recent authorization of all ICIs, the peculiarity of their toxicity profiles and given the lack of safety data from the real life context, our study represents the first comprehensive evaluation of safety data related to ICIs, using the Italian spontaneous reporting system.

Conclusions {#s6}
===========

From our analysis emerged that several serious irADRs have been reported, some of which with fatal outcome. Overall, 2088 ICSRs related to ICIs were collected in the RNF. Twenty percent of these ICSRs reported irADRs. Gastrointestinal and skin toxicities were the most common reported irADRs. In the same study period, 253 ICI-related ICSRs were reported to the Campania PRC. Almost half of regional ICSRs reported ICI-induced irADRs, which were serious in 37.2% of cases and had an unfavorable outcome in 32.2% of cases. Overall, we found 8 fatal cases. Although nivolumab was the ICI most commonly involved in the occurrence of irADRs, most serious cases were ipilimumab-induced, involving gut. Rare irADRs, like those involving renal, cardiac, and ocular systems, have been also reported. Statistically significant differences between cases of irADR and no-irADR emerged for nivolumab and ipilimumab (p \< 0.05). Ipilimumab-induced events occurred earlier compared to nivolumab-induced ones.

Given the clinical relevance of irADRs and considering that innovative drugs are increasingly authorized by accelerated procedures ([@B38]; [@B37]), further safety investigations in real-life context are necessary ([@B40]). We believe that our results could be shared with clinicians that dailies prescribe and administer ICIs or monoclonal antibodies in general. The importance of these innovative drugs in improving patients' clinical conditions is undeniable, but it should be noted that ADRs still represent one of the leading causes of death among inpatients, especially those belonging to frail population or those with multiple comorbidities. Therefore, it is desirable that safety data from a real-life context, such as those presenting in this paper, could serve as source of new information for drugs recently authorized, like many of ICIs nowadays available, and hopefully as a reminder for a systematic and careful monitoring of patients receiving ICIs. Based on our results and in line with other literature data, we believe that oncologists should pay attention to concomitant drugs and diseases, by strictly monitoring those patients who present such risk factors for irADRs onset ([@B8]; [@B21]). Patients should be educated to immediately report any new or worsening symptoms ([@B56]). It is essential to intervene when the severity of irADRs is still slight, avoiding interruption of lifesaving immunotherapeutic treatments.
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